<DOC>
	<DOCNO>NCT01961453</DOCNO>
	<brief_summary>The purpose research study test whether treatment isosorbide mononitrate improve leave ventricular hypertrophy ( `` thicken '' ) put people risk develop heart failure . Once develops , heart failure serious condition thus important find way prevent happen . The investigator reason believe dilate blood vessel specific medication improve thicken heart , increase risk heart failure .</brief_summary>
	<brief_title>Effect Isosorbide Mononitrate Hypertension Improve Left Ventricular Hypertrophy , Fibrosis Myocardial Function</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Hypertrophy , Left Ventricular</mesh_term>
	<mesh_term>Isosorbide-5-mononitrate</mesh_term>
	<mesh_term>Isosorbide Dinitrate</mesh_term>
	<mesh_term>Isosorbide</mesh_term>
	<criteria>Systolic blood pressure &gt; 140 mmHg , diastolic blood pressure &gt; 90 mmHg . An elevated leave ventricular mass index ( define &gt; 60 g/m1.7 woman 80 g/m1.7 men ) OR LV posterior wall thickness &gt; 1.4 cm document clinically indicated echocardiographic examination magnetic resonance imaging scan within previous 12 month . Stable medical therapy define : ( 1 ) No addition removal ACE inhibitor , angiotensin receptor blocker , betablockers , calcium channel blocker 30 day . ( 2 ) No change dosage ACE , angiotensinreceptor blocker , betablockers calciumchannel blocker 100 % 30 day . Current therapy ACE inhibitor , hydralazine statin , show reduce nitrate tolerance . Rhythm sinus rhythm ( i.e. , atrial fibrillation ) . Noncardiac condition limit life expectancy le one year , per physician judgment . Current anticipated future need nitrate therapy . Valve disease ( &gt; mild aortic mitral stenosis ; &gt; moderate aortic mitral regurgitation ) . Hypertrophic cardiomyopathy . Known infiltrative inflammatory myocardial disease ( amyloid , sarcoid ) . Pericardial disease . Primary pulmonary arteriopathy . Have experience myocardial infarction unstable angina , undergone percutaneous transluminal coronary angiography ( PTCA ) coronary artery bypass grafting ( CABG ) within 60 day prior consent , require either PTCA CABG time consent . Resting heart rate ( HR ) &gt; 100 bpm . A reduced LV ejection fraction ( EF &lt; 50 % ) . Known severe liver disease ( AST &gt; 3x normal , alkaline phosphatase bilirubin &gt; 2x normal ) . Patients clinically indicated stress test demonstrate significant ischemia within year enrollment follow percutaneous surgical revascularization . Allergy isosorbide mononitrate . Current therapy phosphodiesterase inhibitor , sildenafil , vardenafil tadalafil , since combination nitrate phosphodiesterase inhibitor result severe hypotension . Therapy rosiglitazone , since combination recommend base epidemiologic data suggest may increase risk myocardial ischemia . Current pregnancy positive urine pregnancy test . Women become pregnant study discontinue trial . Contraindications cardiac MRI : ( ) Central nervous system aneurysm clip ; ( ii ) Implanted neural stimulators ; ( iii ) Implanted cardiac pacemaker defibrillator ; ( iv ) Cochlear implant ; ( v ) Ocular foreign body ( e.g . metal shaving ) ; ( vi ) Other implanted medical device : ( e.g . drug infusion port ) ; ( vii ) Insulin pump ; ( viii ) Metal shrapnel bullet ; ( ix ) Claustrophobia ; ( x ) Extreme obesity render patient unable fit narrowbore scanner ; ( xi ) Unwillingness patient undergo cardiac MRI . All patient metallic implant individually evaluate prior MRI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Isosorbide Mononitrate</keyword>
	<keyword>Myocardial fibrosis</keyword>
</DOC>